Review



enteric-coated mycophenolate sodium (ec-mps; myfortic  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novartis enteric-coated mycophenolate sodium (ec-mps; myfortic
    Enteric Coated Mycophenolate Sodium (Ec Mps; Myfortic, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/ppr0832181-62-19-23
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium (ec-mps; myfortic - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus.
    Article Snippet: Objective: Various studies have revealed that mycophenolic acid (MPA) area under the timeconcentration curve (AUC) may have clinical value in mycophenolate mofetil dose adjustment.. As the full AUC measurement is impractical in clinical practice, several abbreviated AUC profiles using pre-dose, and two or three post-dose samples have been proposed; however, the possible use of lower sampling time profiles has an unquestionable practical interest, and the aim of our study was the evaluation of several two-points algorithms using only one post-dose sample.. Patients and methods: In 60 MPA concentrationtime profiles from 37 adult renal transplant patients treated with mycophenolate mofetil and concomitant tacrolimus, the MPA AUC values were estimated using the three sampling time algorithm (pre-dose, one-half and 2 h post-dose) of Pawinski et al. (Clinical Chemistry 48, 2002, 1497), trapezoidal extrapolated procedure according to Hale et al. (Clinical Pharmacology Therapeutics 64, 1998, 672), and two-points algorithm (pre-dose and 2 h post-dose) proposed by DavidNeto et al. (Clinical Transplantation 19, 2005,19).



    Similar Products

    mycophenolate sodium enteric-coated tablets ec-mps  (Jiangsu Hengrui Medicine)
    90
    Jiangsu Hengrui Medicine mycophenolate sodium enteric-coated tablets ec-mps
    Mycophenolate Sodium Enteric Coated Tablets Ec Mps, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/mycophenolate+sodium+enteric+coated+tablets+ec+mps/pmc12035470__bmjopen___15___4___s001-28-1-17
    Average 90 stars, based on 1 article reviews
    mycophenolate sodium enteric-coated tablets ec-mps - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated mycophenolate sodium (ec-mps; myfortic  (Novartis)
    90
    Novartis enteric-coated mycophenolate sodium (ec-mps; myfortic
    Enteric Coated Mycophenolate Sodium (Ec Mps; Myfortic, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/ppr0832181-62-19-23
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium (ec-mps; myfortic - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated mycophenolate sodium ec-mps  (Novartis)
    90
    Novartis enteric-coated mycophenolate sodium ec-mps
    Enteric Coated Mycophenolate Sodium Ec Mps, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/pmc03485763-83-6-10
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium ec-mps - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated mycophenolate sodium (ec-mps  (Novartis)
    90
    Novartis enteric-coated mycophenolate sodium (ec-mps
    Enteric Coated Mycophenolate Sodium (Ec Mps, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/pmc03599918-106-19-23
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium (ec-mps - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated mycophenolate sodium ec-mps  (Deuter Sport GmbH)
    90
    Deuter Sport GmbH enteric-coated mycophenolate sodium ec-mps
    Enteric Coated Mycophenolate Sodium Ec Mps, supplied by Deuter Sport GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/mycophenolate+mofetil/10__1002_slash_14651858__cd014831__pub2-598-23-19
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium ec-mps - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated mycophenolate sodium (ec-mps, myfortic ®)  (Novartis)
    90
    Novartis enteric-coated mycophenolate sodium (ec-mps, myfortic ®)
    (A) Comparison of overall survival between HTx patients in EC-MPS and MMF groups. (B) Cumulative survival in freedom from treated rejection in heart transplantation patients using MMF vs. EC-MPS. Overall survival rates (A) and cumulative survival in freedom from treated rejection (B) were similar between HTx patients in the EC-MPS and MMF groups. HTx, heart transplantation; EC-MPS, enteric-coated <t>mycophenolate</t> sodium; MMF, mycophenolate mofetil.
    Enteric Coated Mycophenolate Sodium (Ec Mps, Myfortic ®), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/pmc09448250-85-1-7
    Average 90 stars, based on 1 article reviews
    enteric-coated mycophenolate sodium (ec-mps, myfortic ®) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    oral ec-mps mycophenolate sodium enteric-coated tablets myfortic  (Novartis)
    90
    Novartis oral ec-mps mycophenolate sodium enteric-coated tablets myfortic
    (A) Comparison of overall survival between HTx patients in EC-MPS and MMF groups. (B) Cumulative survival in freedom from treated rejection in heart transplantation patients using MMF vs. EC-MPS. Overall survival rates (A) and cumulative survival in freedom from treated rejection (B) were similar between HTx patients in the EC-MPS and MMF groups. HTx, heart transplantation; EC-MPS, enteric-coated <t>mycophenolate</t> sodium; MMF, mycophenolate mofetil.
    Oral Ec Mps Mycophenolate Sodium Enteric Coated Tablets Myfortic, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/pmc09482478-95-26-32
    Average 90 stars, based on 1 article reviews
    oral ec-mps mycophenolate sodium enteric-coated tablets myfortic - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    enteric-coated- mycophenolate sodium ec-mps; myfortic  (Novartis)
    90
    Novartis enteric-coated- mycophenolate sodium ec-mps; myfortic
    MPA exposure and the risk of BPAR. (a) EC-MPS dose in BPAR ( n =14) and non-BPAR ( n =44) groups during the first 12 months. (b) MPA-AUC 0-12h in BPAR and non-BPAR groups at the 1 st week and 1 st month posttransplantation. (c) The percentage of BPAR when MPA-AUC 0-12h <30 mg·h -1 ·L -1 and at ≥30 mg·h -1 · L -1 at the 1 st week and 1 st month posttransplantation. (d) The percentage of MPA-AUC 0-12h range at the 1 st week and 1 st month posttransplantation. * P < 0.05, † P < 0.01. Produced by GraphPad Prism version 6.02 (GraphPad Software Inc., La Jolla, CA, USA). BPAR: Biopsy-proven acute rejection; EC-MPS: <t>Enteric-coated-mycophenolate</t> sodium; MAP: Mycophenolic acid; AUC: Area under the curve.
    Enteric Coated Mycophenolate Sodium Ec Mps; Myfortic, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enteric-coated+mycophenolate+sodium+mps/enteric+coated+mycophenolate+sodium+myfortic/pmc05987500-87-6-12
    Average 90 stars, based on 1 article reviews
    enteric-coated- mycophenolate sodium ec-mps; myfortic - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Comparison of overall survival between HTx patients in EC-MPS and MMF groups. (B) Cumulative survival in freedom from treated rejection in heart transplantation patients using MMF vs. EC-MPS. Overall survival rates (A) and cumulative survival in freedom from treated rejection (B) were similar between HTx patients in the EC-MPS and MMF groups. HTx, heart transplantation; EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil.

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Comparison of mid-term clinical outcome in heart transplantation patients using mycophenolate mofetil vs. enteric-coated mycophenolate sodium

    doi: 10.3389/fcvm.2022.957299

    Figure Lengend Snippet: (A) Comparison of overall survival between HTx patients in EC-MPS and MMF groups. (B) Cumulative survival in freedom from treated rejection in heart transplantation patients using MMF vs. EC-MPS. Overall survival rates (A) and cumulative survival in freedom from treated rejection (B) were similar between HTx patients in the EC-MPS and MMF groups. HTx, heart transplantation; EC-MPS, enteric-coated mycophenolate sodium; MMF, mycophenolate mofetil.

    Article Snippet: Enteric-coated mycophenolate sodium (EC-MPS, Myfortic ® , Novartis Pharmaceuticals, East Hanover, NJ, USA) was developed to reduce GI effects of MMF.

    Techniques: Transplantation Assay

    MPA exposure and the risk of BPAR. (a) EC-MPS dose in BPAR ( n =14) and non-BPAR ( n =44) groups during the first 12 months. (b) MPA-AUC 0-12h in BPAR and non-BPAR groups at the 1 st week and 1 st month posttransplantation. (c) The percentage of BPAR when MPA-AUC 0-12h <30 mg·h -1 ·L -1 and at ≥30 mg·h -1 · L -1 at the 1 st week and 1 st month posttransplantation. (d) The percentage of MPA-AUC 0-12h range at the 1 st week and 1 st month posttransplantation. * P < 0.05, † P < 0.01. Produced by GraphPad Prism version 6.02 (GraphPad Software Inc., La Jolla, CA, USA). BPAR: Biopsy-proven acute rejection; EC-MPS: Enteric-coated-mycophenolate sodium; MAP: Mycophenolic acid; AUC: Area under the curve.

    Journal: Chinese Medical Journal

    Article Title: Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation

    doi: 10.4103/0366-6999.232797

    Figure Lengend Snippet: MPA exposure and the risk of BPAR. (a) EC-MPS dose in BPAR ( n =14) and non-BPAR ( n =44) groups during the first 12 months. (b) MPA-AUC 0-12h in BPAR and non-BPAR groups at the 1 st week and 1 st month posttransplantation. (c) The percentage of BPAR when MPA-AUC 0-12h <30 mg·h -1 ·L -1 and at ≥30 mg·h -1 · L -1 at the 1 st week and 1 st month posttransplantation. (d) The percentage of MPA-AUC 0-12h range at the 1 st week and 1 st month posttransplantation. * P < 0.05, † P < 0.01. Produced by GraphPad Prism version 6.02 (GraphPad Software Inc., La Jolla, CA, USA). BPAR: Biopsy-proven acute rejection; EC-MPS: Enteric-coated-mycophenolate sodium; MAP: Mycophenolic acid; AUC: Area under the curve.

    Article Snippet: A triple immunosuppressive regimen of enteric-coated- mycophenolate sodium (EC-MPS; myfortic ® , Novartis, Basel, Switzerland), tacrolimus (Tac), and prednisone (pred) was the initial maintenance immunosuppressive regimen used in all patients.

    Techniques: Produced, Software